87 studies found for:    "polycystic kidney disease"
Show Display Options
Rank Status Study
21 Unknown  Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Triptolide-Containing Formulation;   Drug: Placebo
22 Completed A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
23 Completed Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:
24 Completed A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
25 Terminated Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
Condition: Polycystic Kidney
Interventions: Drug: tripterygium wilfordii;   Drug: Emodin
26 Not yet recruiting The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Device: Vessix
27 Not yet recruiting Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Metformin;   Other: Placebo
28 Terminated The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
Condition: Polycystic Kidney, Autosomal Dominant
Intervention:
29 Completed A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: tolvaptan
30 Recruiting Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Condition: Polycystic Kidney Disease
Interventions: Drug: Pioglitazone;   Drug: Placebo
31 Completed Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
Conditions: Chronic Kidney Disease;   Polycystic Kidney, Autosomal Dominant
Intervention:
32 Completed Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: pravastatin;   Drug: Placebo
33 Completed
Has Results
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Bosutinib;   Drug: Placebo
34 Completed Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Long-acting somatostatin;   Other: Saline solution
35 Completed Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
Condition: Polycystic Kidney Disease
Intervention:
36 Terminated
Has Results
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Rapamycin;   Other: Standard of Care-Placebo
37 Recruiting Clinical and Molecular Investigations Into Ciliopathies
Conditions: Autosomal Recessive Polycystic Kidney Disease;   Congenital Hepatic Fibrosis;   Caroli's Disease;   Polycystic Kidney Disease;   Joubert Syndrome;   Cerebro-Oculo-Renal Syndromes;   COACH Syndrome;   Senior-Loken Syndrome;   Dekaban-Arima Syndrome;   Cogan Oculomotor Apraxia;   Nephronophthisis;   Bardet-Biedl Syndrome;   Alstrom Syndrome;   Oral-Facial-Digital Syndrome
Intervention:
38 Active, not recruiting Open-Label Tolvaptan Study in Subjects With ADPKD
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Tolvaptan
39 Completed Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD
Condition: Polycystic Kidney Disease, Autosomal Dominant
Interventions: Drug: tolvaptan;   Drug: Placebo
40 Active, not recruiting Study of Lanreotide to Treat Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Lanreotide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years